Company intelligence / Profile preview

Stellular Bio

Watertown, Massachusetts, United Statesstellularbio.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Stellular Bio develops a novel regenerative medicine approach using engineered platelet-derived biologics and allogeneic stem-cell-derived PLCs. Their lead program targets ocular surface diseases such as dry eye associated with Sjogren’s syndrome. The company has demonstrated preclinical efficacy and established scalable manufacturing processes, with plans to enter clinical trials soon. Their broader vision includes expanding into additional ocular indications using their tunable PRB/PLC platforms.[1][2][3]

Therapeutic areas: ImmunologyOphthalmology
Modalities: Regenerative biologics (platelet-derived)Allogeneic stem-cell-derived platelet-like cells (PLCs)[1][3]Engineered cell therapies[3]
Industry: Biotech

Drug pipeline

1 asset

STLR-201

Preclinical

Beyond the preview

Go deeper on Stellular Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stellular Bio.

Explore the full profile